Q3 2025 Jaguar Health Inc Earnings Call Transcript
Key Points
- Jaguar Health Inc (JAGX) reported a 4% increase in combined net revenue for the third quarter of 2025, reaching approximately $3.1 million.
- The company has received orphan drug designation in the US and Europe for crofelemer for both short bowel syndrome and microvillus inclusion disease (MVID), highlighting its potential in treating rare diseases.
- Crofelemer has shown a significant reduction in parenteral support for patients with intestinal failure, which could improve quality of life and reduce treatment toxicity.
- Jaguar Health Inc (JAGX) is actively negotiating business development partnerships to generate non-dilutive funding for its late-stage health products.
- The company is pursuing multiple business development negotiations for its animal health product, Canalevia, aiming for regulatory approval and commercialization for general diarrhea in dogs globally.
- Despite the revenue increase, the company reported a net loss attributable to common shareholders of $9.5 million for the third quarter of 2025.
- Mytesi prescription volume decreased by 3.6% compared to the third quarter of the previous year.
- Loss from operations increased slightly from $7.2 million in the third quarter of 2024 to $7.3 million in the same period in 2025.
- The company faces significant challenges in achieving regulatory approval and commercialization for its products, which are still in the development stage.
- Jaguar Health Inc (JAGX) continues to operate at a net loss, with non-GAAP recurring EBITDA showing a net loss of $8.9 million for the third quarter of 2025.
Greetings, and welcome to the Jaguar Health's Investor Webcast. (Operator Instructions) As a reminder, this conference is being recorded. Before I turn the call over to management, I'd like to remind you that management make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends, product initiatives, including products in the development stage, which may achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events.
While management believes its assumptions, expectations and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
